Pharmaceutical News

RSS

iOWH's semisynthetic ART enters production, distribution phase to combat malaria

The Institute for OneWorld Health, a non-profit drug development organization, announced today that its development of an alternative source of artemisinin using pioneering synthetic biology technology has successfully entered the production and distribution phase.

18 Apr 2011

Biotech Synergy concludes EP-2101 asset transfer, cancer epitopes related portfolio

Biotech Synergy has concluded the asset transfer of multi-epitope cancer vaccine product formerly known as EP-2101 and cancer epitopes related portfolio. Emile Loria, M.D., former President and Chief Business Officer of IDM and former President & CEO of Epimmune, is the founder of Biotech Synergy.

18 Apr 2011

True 2 Beauty launches new sexual enhancement supplements

True 2 Beauty Inc., a leading distributor of male and female sexual potency pills and liquid products in the United States, is pleased to announce the launch of a new, additional line of sexual enhancement supplements for men and women under the brand Blue Diamond and Pink Diamond.

18 Apr 2011

CHMP adopts EU positive opinion for TYSABRI labeling with anti-JCV antibody status

Biogen Idec and Elan Corporation, plc today announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion for inclusion of an additional risk factor, anti-JC virus (JCV) antibody status, to the product label for TYSABRI in the European Union.

18 Apr 2011

Ipsen, Active Biotech sign deal to co-develop and commercialize TASQ

Active Biotech AB and Ipsen announced today that they have entered into a broad partnership to co-develop and commercialize Active Biotech's investigational compound Tasquinimod "TASQ".

18 Apr 2011

Scientists develop new compound for multiple sclerosis treatment

Scientists from the Florida campus of The Scripps Research Institute have developed the first of a new class of highly selective compounds that effectively suppresses the severity of multiple sclerosis in animal models.

18 Apr 2011

Eye physicians need to include low-cost molecular medicine in their tool box

Dr. Richer, speaking at his 4th annual Nutrition & The Eye conference, April 16-17, hosted by the College of Optometry at the University of Missouri in St. Louis, says molecular medicine is beginning to provide hope for patients with declining sight when all other therapies have been exhausted.

18 Apr 2011

Pharmatek receives U.S. DEA approval for Schedule I-V controlled substance analysis

Pharmatek Laboratories, Inc., a premier contract development and manufacturing organization supporting the pharmaceutical industry, announced that it has been approved by the United States Drug Enforcement Agency for the analysis of Schedules I through V controlled substances, complementing its existing license to develop and manufacture drug products containing Schedules IV and V controlled substances.

18 Apr 2011

Patients with schizophrenia can benefit from L-lysine treatment

Schizophrenia is a serious mental disorder that currently affects about one in every 200 people. Most patients find some relief from their symptoms by treatment with antipsychotics, however they may still suffer from cognitive and negative symptoms.

18 Apr 2011

Scientists discover new clues about mechanism behind losartan drug's protective effects

The Johns Hopkins researchers who first showed that the commonly used blood pressure drug losartan may help prevent life-threatening aneurysms of the aorta in patients with Marfan syndrome have now discovered new clues about the precise mechanism behind the drug's protective effects.

16 Apr 2011

Kakadu Complex can protect against high insulin levels

Following 27 years of research, Australian wild foods are now scientifically recognized as the world's most nutritious plant foods. Their food quality sustained the world's longest living culture -- the Australian Aborigines -- for over 60,000 years, and in better health than we have today.

16 Apr 2011

AHF commends U.S. Congress for strong bipartisan commitment to AIDS

AIDS Healthcare Foundation today commended the United States Congress for showing a strong bipartisan commitment to AIDS in passing the fiscal year 2011 budget earlier this afternoon, a budget that despite severe cost-cutting mentality in Washington, included a $48 million overall increase in the $883 million allocated for the nation's AIDS Drug Assistance Program, a network of federal and state funded programs that provide life-saving HIV treatments to low income, uninsured, and underinsured individuals living with HIV/AIDS nationwide.

16 Apr 2011

NVP-BEZ235 inhibits growth of ovarian cancer cells, increases survival: Study

An experimental drug that blocks two points of a crucial cancer cell signaling pathway inhibits the growth of ovarian cancer cells and significantly increases survival in an ovarian cancer mouse model, a study at UCLA's Jonsson Comprehensive Cancer Center has found.

16 Apr 2011

Probiotic may reduce rate of recurrent urinary tract infections in women

Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.

16 Apr 2011

Johnson & Johnson provides further details regarding distribution rights for REMICADE, SIMPONI

Johnson & Johnson provided additional information today on its amended agreement with Merck regarding distribution rights for REMICADE (infliximab) and SIMPONI (golimumab) in markets outside the United States. The amended agreement announced today in a separate news release from both companies concludes a pending arbitration, which had been filed by Johnson & Johnson in May 2009.

16 Apr 2011

Eli Lilly receives FDA complete response letter for liprotamase NDA

Eli Lilly and Company has received a complete response letter from the U.S. Food and Drug Administration for its New Drug Application for liprotamase, a non-porcine pancreatic enzyme replacement therapy, under investigation for the treatment of exocrine pancreatic insufficiency.

16 Apr 2011

Boehringer Ingelheim's dabigatran etexilate receives positive opinion from EMA committee

Boehringer Ingelheim's novel oral anticoagulant dabigatran etexilate, received a positive opinion from the European Medicines Agency's medicinal committee today.

16 Apr 2011

U.S. District Court grants preliminary injunction to POZEN's Treximet patent lawsuit

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today that the U.S. District Court for the Eastern District of Texas has granted a preliminary injunction ordering Par Pharmaceutical Inc. not to make, use, sell, offer to sell, or import into the United States a generic version of sumatriptan/naproxen sodium that competes with Treximet sold by GlaxoSmithKline in the United States under an exclusive license from the Company.

15 Apr 2011

JNJ, Merck sign distribution agreement for REMICADE and SIMPONI

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Johnson & Johnson (NYSE: JNJ) and its subsidiary Centocor Ortho Biotech Inc., today announced that the companies have reached agreement to amend the distribution rights to REMICADE and SIMPONI, which treat chronic inflammatory diseases such as rheumatoid arthritis.

15 Apr 2011

Patients with COPD can benefit from ICS use

Patients with chronic obstructive pulmonary disease who are hospitalized for pneumonia and treated with inhaled corticosteroids have decreased mortality when compared to those who are not treated with ICS, according to a retrospective analysis of almost 16,000 COPD patients admitted to VA hospitals.

15 Apr 2011

Pharmaceutical News

iOWH's semisynthetic ART enters production, distribution phase to combat malaria

Biotech Synergy concludes EP-2101 asset transfer, cancer epitopes related portfolio

True 2 Beauty launches new sexual enhancement supplements

CHMP adopts EU positive opinion for TYSABRI labeling with anti-JCV antibody status

Ipsen, Active Biotech sign deal to co-develop and commercialize TASQ

Scientists develop new compound for multiple sclerosis treatment

Eye physicians need to include low-cost molecular medicine in their tool box

Pharmatek receives U.S. DEA approval for Schedule I-V controlled substance analysis

Patients with schizophrenia can benefit from L-lysine treatment

Scientists discover new clues about mechanism behind losartan drug's protective effects

Kakadu Complex can protect against high insulin levels

AHF commends U.S. Congress for strong bipartisan commitment to AIDS

NVP-BEZ235 inhibits growth of ovarian cancer cells, increases survival: Study

Probiotic may reduce rate of recurrent urinary tract infections in women

Johnson & Johnson provides further details regarding distribution rights for REMICADE, SIMPONI

Eli Lilly receives FDA complete response letter for liprotamase NDA

Boehringer Ingelheim's dabigatran etexilate receives positive opinion from EMA committee

U.S. District Court grants preliminary injunction to POZEN's Treximet patent lawsuit

JNJ, Merck sign distribution agreement for REMICADE and SIMPONI

Patients with COPD can benefit from ICS use

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News